Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents
about
Promising oncolytic agents for metastatic breast cancer treatmentHAdV-C6 Is a More Relevant Challenge Virus than HAdV-C5 for Testing Antiviral Drugs with the Immunosuppressed Syrian Hamster Model.Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic AdenovirusInfection and killing of multiple myeloma by adenovirusesChemoselective attachment of small molecule effector functionality to human adenoviruses facilitates gene delivery to cancer cells.Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Intratumoral versus intravenous gene therapy using a transcriptionally targeted viral vector in an orthotopic hepatocellular carcinoma rat model.Characterization of species C human adenovirus serotype 6 (Ad6)Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer.Mining the adenovirus virome for oncolytics against multiple solid tumor typesComparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma modelSpecies D adenoviruses as oncolytics against B-cell cancers.Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors.Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers.Circulating antibodies and macrophages as modulators of adenovirus pharmacologyEvaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy.Efficacy of CD46-targeting chimeric Ad5/35 adenoviral gene therapy for colorectal cancers.Native and engineered tropism of vectors derived from a rare species D adenovirus serotype 43.Transgene Expression and Host Cell Responses to Replication-Defective, Single-Cycle, and Replication-Competent Adenovirus Vectors.Advances and future challenges in adenoviral vector pharmacology and targeting.Serotype chimeric human adenoviruses for cancer gene therapy.Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5Comparison of the Life Cycles of Genetically Distant Species C and Species D Human Adenoviruses Ad6 and Ad26 in Human Cells.Oncolytic virotherapy for head and neck cancer: current research and future developments.Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.Viral dose, radioiodide uptake, and delayed efflux in adenovirus-mediated NIS radiovirotherapy correlates with treatment efficacy.Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.Single-cycle adenovirus vectors in the current vaccine landscape.Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer.Human adenovirus type 17 from species D transduces endothelial cells and human CD46 is involved in cell entry
P2860
Q26830620-E737D137-87FB-4C37-A5AA-FF2651211060Q32183133-7C9F2740-383B-49A1-AD7F-9D64007AB1F7Q33633287-19BEDAA0-A7C6-4ABD-9094-FC8AD335A522Q33691833-F03E753C-4E38-4B33-BFDC-CEA48E1E7136Q33862005-67D5EB75-2B4A-46C5-9552-C88D4B80EBB4Q33906116-E0E26133-8648-4C4E-AB9E-E8F88D148F7BQ34042354-0F85C1A9-D8A7-41AC-BDC8-0B8AD2B5FDE1Q34669375-1BEB80B2-4BFA-4443-98CC-A534B92FBE7DQ35086122-588BB60D-DA26-4033-B09A-4BDC2CC31C7EQ35223768-6294745E-1D81-4DAD-B405-3B8BEEC637B2Q35226109-68EAA8BF-75F6-4294-AF13-6BA9CEE9CDAEQ35511348-08AE2569-BA81-4D38-8D98-8C830C243B0AQ35826589-2C6C494C-3B4A-448A-B668-3978C138129AQ36594178-090D6DB0-FB1E-49FC-BD85-DEE109706F21Q36759761-4F552B09-5358-4441-9511-4B87CD2D89EFQ37100291-853A2210-1453-409F-B97D-0A7EE8534F8AQ37437450-E7E066CF-2283-4977-8654-F216C3653D04Q37619767-9C5A9D09-4156-4064-B9B4-73EAA645EC9FQ37676263-81CB4885-8086-4A00-9034-47378099A6CEQ37859842-72029D94-2946-4367-B804-9817C59B63FBQ37945193-3326C594-C644-443E-ACE5-ED3A74920F13Q38714311-CD30F72C-1FA5-47FE-9D52-9C5F7FD8C82AQ38831184-A7A97F47-027D-4DD7-A14A-19673AC83773Q38924562-74FD3530-4FB7-4EC1-95AD-E3CE2868AD9CQ39020219-F3A4851A-341B-4F19-AD8F-777157627DF5Q39107708-AFCEE67C-0577-4DD3-A712-08239EA75ACDQ39280068-D3D46DC6-CCA4-44F3-8BF7-4D9D9C521AC1Q39442539-B3538984-7D06-477E-8E3B-C0947DCE1E7CQ47282517-030A5622-3F75-4CF7-A53F-DFB900AF44DCQ55423899-E4821C89-F8E9-4900-BB5F-EBE0E54C4AD8Q58759854-969C2273-8F9F-41DA-B1CA-63A3AADF6426
P2860
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents
@en
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents.
@nl
type
label
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents
@en
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents.
@nl
prefLabel
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents
@en
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents.
@nl
P2093
P2860
P1433
P1476
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents
@en
P2093
Elena V Shashkova
Michael A Barry
Shannon M May
P2860
P304
P356
10.1016/J.VIROL.2009.08.038
P407
P577
2009-09-18T00:00:00Z